About
About Accelerate Diagnostics Inc
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. The company was incorporated in 1982 and is headquartered in Tucson, Arizona.
Visit company website
5 years, 5 months ago
Accelerate Diagnostics Inc is currently in a long term downtrend where the price is trading 18.2% below its 200 day moving average.
From a valuation standpoint, the stock is 227.0% more expensive than other stocks from the Other sector with a price to sales ratio of 41.5.
Accelerate Diagnostics Inc's total revenue sank by 10.4% to $3M since the same quarter in the previous year.
Its net income has increased by 11.4% to $-19M since the same quarter in the previous year.
Finally, its free cash flow grew by 26.4% to $-10M since the same quarter in the previous year.
Based on the above factors, Accelerate Diagnostics Inc gets an overall score of 2/5.